High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population

ConclusionA relativelyhigh incidence of pathogenic non-founder BRCA1/2 mutations wasobserved in a founder population. The Manchester scoring system predicted the probability of non-founder pathogenic mutations with high accuracy.
Source: Hereditary Cancer in Clinical Practice - Category: Cancer & Oncology Source Type: research